Diurnal Group PLC Diurnal to present research at ENDO 2022
07 June 2022 - 10:00PM
RNS Non-Regulatory
TIDMDNL
Diurnal Group PLC
07 June 2022
7 June 2022
Diurnal Group plc
("Diurnal" or the "Company")
Diurnal to present research into the treatment of congenital
adrenal hyperplasia at ENDO 2022
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, will be presenting research findings on the treatment and
management of congenital adrenal hyperplasia (CAH) at this year ' s
American Endocrine Society meeting, ENDO 2022, which will be taking
place between 11-14 June 2022 in Atlanta, USA.
Over the four-day meeting, the following topics will be
presented:
-- Comparison of prednisolone versus hydrocortisone
modified-release hard capsules (Efmody(R) ) in the treatment of CAH
.
-- A de novo model for measuring long-term health effects of
hydrocortisone modified-release hard capsules in adult and
adolescent patients with classic CAH.
CAH occurs when the production of cortisol from the adrenal
gland is limited due to a genetic deficiency. CAH is associated
with over-production of male sex hormones resulting in ambiguous
genitalia at birth, precocious sexual development, infertility in
men and women, and increased mortality through adrenal crisis.
Around 450,000 people globally are estimated to be living with a
CAH disorder yet there is no standard treatment. Instead, a variety
of steroids are used but data shows around two thirds of people
living with CAH still have problems with disease control[i].
Richard Bungay, Interim Chief Executive Officer of Diurnal
commented:
"These presentations at ENDO follow our very well attended
presentations at the European Congress of Endocrinology meeting in
Europe last month. Diurnal is committed to supporting research into
diseases of cortisol deficiency and developing solutions to support
patients with these life-long disorders. The interest we have
received from the world's leading endocrinologists demonstrates the
progress we are making in the treatment and management of diseases
of cortisol deficiency."
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Richard Bungay, Interim Chief Executive Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Joint Corporate Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
Stifel Nicolaus Europe Limited (Joint Corporate +44 (0) 20 7710
Broker) 7600
Healthcare Investment Banking: Nicholas Moore,
Samira Essebiyea, William Palmer-Brown
Corporate Broking: Nick Adams, Nick Harland
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Alex Davis
+44 (0) 173 782
Vane Percy & Roberts (Medical Communications) 1890
Simon Vane Percy
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty
pharmaceutical company dedicated to developing hormone therapeutics
to aid lifelong treatment for rare and chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency, hypogonadism and hypothyroidism. Its expertise and
innovative research activities focus on circadian-based
endocrinology to yield novel product candidates in the rare and
chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.com
Date of Preparation: June 2022 Code: CORP-GLO-0039
[i] Mallappa, A., Merke, D.P. Management challenges and
therapeutic advances in congenital adrenal hyperplasia. Nat Rev
Endocrinol 18, 337-352 (2022).
https://doi.org/10.1038/s41574-022-00655-w
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGGVMNMGZZM
(END) Dow Jones Newswires
June 07, 2022 08:00 ET (12:00 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024